Adam Windish

Adam Windish is the CEO of BRITISH CANNABIS™ Group, which includes BRITISH CANNABIS™, BRITISH CANNABIS™ Medicines and Canndr™. He joined BRITISH CANNABIS™ to establish its medical division and has helped grow the group into one of the UK’s most recognised names in cannabinoid healthcare.

With over a decade of international experience, Adam has developed a deep understanding of the cannabis industry, with broad exposure across the supply chain including cultivation, extraction, healthcare delivery, product development, compliance and commercial strategy. He has overseen medical cannabis clinics in established international markets and continues to apply that knowledge to support best practice in the UK.

Adam is a strong advocate for responsible industry growth, improved patient access and regulatory clarity. He has also contributed to legal and policy discussions aimed at protecting patients and strengthening confidence in the UK framework.

His broader background spans healthcare, consultancy, product development and real estate, bringing together strategic insight and operational experience across regulated markets.

Now in his role as CEO, Adam is focused on supporting the professionalisation of the UK cannabis sector, promoting transparency, ethical leadership and meaningful collaboration across all stakeholders. He is committed to helping shape a sustainable, clinically credible and patient-first model for cannabinoid-based care in the UK.